Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 2
2005 1
2006 2
2007 1
2008 1
2010 1
2011 3
2012 2
2013 2
2014 1
2016 4
2017 5
2018 3
2019 2
2020 2
2021 3
2022 4
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

35 results
Results by year
Filters applied: . Clear all
Page 1
Anagrelide for Gastrointestinal Stromal Tumor.
Pulkka OP, Gebreyohannes YK, Wozniak A, Mpindi JP, Tynninen O, Icay K, Cervera A, Keskitalo S, Murumägi A, Kulesskiy E, Laaksonen M, Wennerberg K, Varjosalo M, Laakkonen P, Lehtonen R, Hautaniemi S, Kallioniemi O, Schöffski P, Sihto H, Joensuu H. Pulkka OP, et al. Among authors: murumagi a. Clin Cancer Res. 2019 Mar 1;25(5):1676-1687. doi: 10.1158/1078-0432.CCR-18-0815. Epub 2018 Dec 7. Clin Cancer Res. 2019. PMID: 30530703
Consistency in drug response profiling.
Mpindi JP, Yadav B, Östling P, Gautam P, Malani D, Murumägi A, Hirasawa A, Kangaspeska S, Wennerberg K, Kallioniemi O, Aittokallio T. Mpindi JP, et al. Among authors: murumagi a. Nature. 2016 Nov 30;540(7631):E5-E6. doi: 10.1038/nature20171. Nature. 2016. PMID: 27905421 No abstract available.
Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma.
Murumägi A, Ungureanu D, Khan S, Arjama M, Välimäki K, Ianevski A, Ianevski P, Bergström R, Dini A, Kanerva A, Koivisto-Korander R, Tapper J, Lassus H, Loukovaara M, Mägi A, Hirasawa A, Aoki D, Pietiäinen V, Pellinen T, Bützow R, Aittokallio T, Kallioniemi O. Murumägi A, et al. Br J Cancer. 2022 Dec 7. doi: 10.1038/s41416-022-02067-z. Online ahead of print. Br J Cancer. 2022. PMID: 36476658
Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML.
Malani D, Murumägi A, Yadav B, Kontro M, Eldfors S, Kumar A, Karjalainen R, Majumder MM, Ojamies P, Pemovska T, Wennerberg K, Heckman C, Porkka K, Wolf M, Aittokallio T, Kallioniemi O. Malani D, et al. Among authors: murumagi a. Leukemia. 2017 May;31(5):1187-1195. doi: 10.1038/leu.2016.314. Epub 2016 Nov 11. Leukemia. 2017. PMID: 27833094 Free PMC article.
Multiomics characterization implicates PTK7 in ovarian cancer EMT and cell plasticity and offers strategies for therapeutic intervention.
Raivola J, Dini A, Karvonen H, Piki E, Salokas K, Niininen W, Kaleva L, Zhang K, Arjama M, Gudoityte G, Seashore-Ludlow B, Varjosalo M, Kallioniemi O, Hautaniemi S, Murumägi A, Ungureanu D. Raivola J, et al. Among authors: murumagi a. Cell Death Dis. 2022 Aug 17;13(8):714. doi: 10.1038/s41419-022-05161-5. Cell Death Dis. 2022. PMID: 35977930 Free PMC article.
KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia.
Malani D, Yadav B, Kumar A, Potdar S, Kontro M, Kankainen M, Javarappa KK, Porkka K, Wolf M, Aittokallio T, Wennerberg K, Heckman CA, Murumägi A, Kallioniemi O. Malani D, et al. Among authors: murumagi a. Leukemia. 2020 Oct;34(10):2780-2784. doi: 10.1038/s41375-020-0978-7. Epub 2020 Jul 17. Leukemia. 2020. PMID: 32678289 No abstract available.
35 results